PTC Therapeutics jumped after the FDA approved Sephience for PKU patients as young as one month. The label was supported by strong Phase 3 data showing sustained drops in phenylalanine. Analysts flagged it as a key catalyst; Citi raised its price target to $50. Retail sentiment turned 'extremely bullish' on Stocktwits.